$25MRound, 10 November 2026
PsiThera closed a $25 million financing to advance oral TNFα and TL1A therapies and begin IND-enabling studies.
- Amount
- $25M
- Announced
- 10 November 2026
- Investors
- AbbVie Ventures, Lumination Capital, Samsara BioCapital, Lightstone Ventures
- Use of funds
- Fund operations, development candidate nomination and IND-enabling studies for oral TNFα inhibitor, TL1A lead optimization
- Checked
- Announced by the company
- Source
- PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in Immunology globenewswire.com